Related Experiment Video
Updated: Feb 14, 2026

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells
Published on: February 18, 2015
Therapeutic cancer vaccines: From initial findings to prospects
Qian Song1, Cheng-Dong Zhang2, Xiang-Hua Wu1
1Department of Medical Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, 130 Dong-An Road, Shanghai 200032, China.
Abstract:
With the approval of the first therapeutic cancer vaccine by US Food and Drug Administration, numerous therapeutic cancer vaccines have been under clinical trials with an inspiring antitumor immune response in cancer patients. Though there is no therapeutic cancer vaccine showing clinical efficacy in phase III trials, recent advances in personalized cancer vaccine based on neoantigens have emerged as an efficient way to induce tumor regression. In this review, we discuss the selection methods of tumor specific antigen and mainly focus on the development of therapeutic cancer vaccine strategies. Besides, we highlight the newly developed personalized cancer vaccine as a novel therapeutic approach for cancer patients. Finally, we outline the recent development of therapeutic cancer vaccine in clinical trials.
Insights
Personalized cancer vaccines targeting neoantigens show promise for inducing tumor regression. This review explores therapeutic cancer vaccine strategies and their clinical trial developments.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- The first therapeutic cancer vaccine approval marked a milestone.
- Numerous therapeutic cancer vaccines are in clinical trials, showing antitumor immune responses.
Purpose of the Study:
- To review therapeutic cancer vaccine strategies.
- To highlight personalized cancer vaccines based on neoantigens.
- To discuss tumor-specific antigen selection methods.
Main Methods:
- Review of clinical trial data.
- Analysis of therapeutic cancer vaccine strategies.
- Focus on neoantigen-based vaccine development.
Main Results:
- Personalized cancer vaccines demonstrate potential for tumor regression.
- Neoantigen-based vaccines are an emerging efficient therapeutic approach.
Conclusions:
- Therapeutic cancer vaccines are advancing, with personalized neoantigen vaccines showing significant promise.
- Further clinical trials are crucial for demonstrating efficacy.
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Vaccinations
Initiation of Translation
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
Initiation of Translation
Finding the Center of Gravity
Transcription Initiation
The promoters and enhancers and their accessory proteins allow tight regulation of...

